Logo

PDSB

PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation • NASDAQ
$0.77 ▼ -5.20% (-0.04)
Market Cap $37.76 M
52w High $2.46
52w Low $0.73
Dividend Yield 0%
P/E -0.95
Volume 355.75K
Outstanding Shares 48.97M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $8.14M ▲ $-9.009M ▲ 0% $-0.19 ▲ $-7.859M ▼
Q2-2025 $0 $7.623M ▼ $-9.434M ▼ 0% $-0.21 $-7.284M ▲
Q1-2025 $0 $9.106M ▲ $-8.489M ▼ 0% $-0.21 ▲ $-8.722M ▼
Q4-2024 $0 $7.345M ▼ $-7.952M ▲ 0% $-0.22 ▲ $-6.842M ▲
Q3-2024 $0 $10.179M $-10.727M 0% $-0.29 $-9.506M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $26.199M ▼ $34.706M ▼ $25.252M ▲ $9.454M ▼
Q2-2025 $31.873M ▼ $40.476M ▼ $24.516M ▼ $15.96M ▼
Q1-2025 $39.979M ▼ $47.029M ▲ $24.666M ▼ $22.362M ▲
Q4-2024 $41.69M ▼ $45.359M ▼ $26.354M ▼ $19.005M ▼
Q3-2024 $49.751M $52.451M $30.45M $22.001M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-9.009M ▲ $-5.916M ▲ $0 $241.205K ▼ $-5.675M ▲ $-5.916M ▲
Q2-2025 $-9.434M ▼ $-9.101M ▼ $0 $995.944K ▼ $-8.105M ▼ $-9.101M ▼
Q1-2025 $-8.489M ▼ $-9.032M ▼ $0 $7.321M ▲ $-1.711M ▲ $-9.032M ▼
Q4-2024 $-7.952M ▲ $-8.234M ▼ $0 ▲ $172.778K ▲ $-8.062M ▼ $-8.234M ▼
Q3-2024 $-10.727M $-8M $-1 $17.216K $-7.982M $-8M

Five-Year Company Overview

Income Statement

Income Statement PDS Biotechnology is still a pure R&D-stage biotech company with no product sales yet. Its income statement is dominated by research and development and other operating costs, leading to steady losses each year. Those losses have grown as the company has advanced more trials and expanded its pipeline, which is normal for a clinical-stage biotech but means the business is entirely dependent on external funding rather than internal profits for now.

Balance Sheet

Balance Sheet The balance sheet is relatively small and simple. Cash makes up most of the assets, with only a thin layer of other assets and equity. There is a modest amount of debt in recent years, and shareholder equity has been gradually eroded by ongoing losses. Overall, the company looks capital-light but financially fragile, with its strength largely tied to how much cash it can raise and how carefully it manages that cash.

Cash Flow

Cash Flow Cash flows are consistently negative from operating activities, reflecting spending on trials, staff, and overhead without any offsetting revenue. Free cash flow is also negative, and there is essentially no spending on heavy equipment or facilities. This pattern is typical for a small biotech, but it underscores that the company will likely need periodic capital raises or partnerships to keep funding its programs.

Competitive Edge

Competitive Edge PDSB’s competitive position rests on its proprietary Versamune and Infectimune platforms, which are designed to improve how the immune system targets cancer and infectious diseases. The firm benefits from patents, a differentiated mechanism of action, and collaborations with respected partners like the National Cancer Institute and Merck. At the same time, it operates in a very crowded and fast-moving immuno-oncology field, where many larger, better-funded players are pursuing overlapping cancer indications, so maintaining a durable edge will depend on how compelling and reproducible its clinical data prove to be.

Innovation and R&D

Innovation and R&D Innovation is the clear focus and strength of the company. Versamune aims to generate powerful, targeted T-cell responses against cancers such as HPV-positive head and neck cancers, while PDS01ADC adds targeted delivery of IL-12 to boost the immune attack in tumors. The pipeline extends into MUC1-positive cancers and a universal flu vaccine based on Infectimune, suggesting a versatile platform rather than a single-product story. Clinical collaborations, progressing Phase 2 trials, and early-stage infectious disease work all point to an aggressive R&D strategy, but also to high scientific and regulatory risk typical of this stage.

Summary

PDS Biotechnology is a small, clinical-stage biotech with promising immunotherapy platforms but no commercial products yet. Financially, it runs ongoing losses, burns cash on R&D, and operates with a modest, cash-heavy but fragile balance sheet, implying reliance on future financings or partnerships. Strategically, it targets areas of high unmet need with differentiated T-cell–focused technologies and has attracted credible collaborators, which supports its scientific story. The overall picture is of a high-risk, high-uncertainty development-stage company whose future will hinge on clinical trial outcomes, regulatory decisions, and continued access to capital, rather than on current financial performance.

NEWS

November 13, 2025 · 7:30 AM UTC

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Read more

November 11, 2025 · 3:31 PM UTC

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Read more

November 10, 2025 · 8:30 AM UTC

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Read more

November 6, 2025 · 8:00 AM UTC

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Read more

October 30, 2025 · 8:00 AM UTC

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Read more